Preparation method of high-throughput airway inflammatory drug screening cell model based on NF-kappaB signaling pathway, and application of cell model

A technology of airway inflammation and cell model, applied in the field of biomedicine, can solve the problems of low efficiency, error, cumbersome and time-consuming detection steps, etc.

Active Publication Date: 2018-12-14
ZHEJIANG ACAD OF TRADITIONAL CHINESE MEDICINE
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] According to the reported literature on NF-κB detection, current NF-κB detection methods generally include immunohistochemistry, reverse transcriptase-polymerase chain reaction (Reverse transcriptase-polymerase chain reaction, RT-PCR), protein immunoassay Western blot, but the common problem of the three is that the detection steps are cumbersome and time-consuming, and there are certain limitations in the rapid and high-throughput screening of airway inflammation drugs
Immunohistochemical staining is simple to operate, highly sensitive, and specific, and can combine morphology and antigen localization, but there are many factors that affect immunohistochemistry. For paraffin sections, the problem of stripping is common, which can affect staining and results For cell slide...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method of high-throughput airway inflammatory drug screening cell model based on NF-kappaB signaling pathway, and application of cell model
  • Preparation method of high-throughput airway inflammatory drug screening cell model based on NF-kappaB signaling pathway, and application of cell model
  • Preparation method of high-throughput airway inflammatory drug screening cell model based on NF-kappaB signaling pathway, and application of cell model

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] 1. Materials, reagent preparation, cell culture and HTRF assay method

[0042] 1.1 Reagents: NF-κB detection kit (Cisbio company, batch number 10-009-13); TNF-α (Peprotech company, batch number 101373); LPS (sigma company, batch number: 017M4112V); DMEM / F12 complete medium (containing FBS, bFGF, Insulin, Hydrocortisone, Penicillin, Streptomycin, produced by Qishi Biotechnology Co., Ltd., batch number 20150920); 0.25% Trypsin (containing 0.02% EDTA, Gino Biomedical Technology Co., Ltd., batch number 17052901); fetal bovine serum (Zhejiang Tianhang Biotechnology Co., Ltd., batch number 20171011); PBS (Jinuo Biomedical Technology Co., Ltd., batch number 17092406); dimethyl sulfoxide (DMSO) was of analytical grade, provided by Hewlett-Packard Chemical Instrument Co., Ltd.

[0043] 1.2 Cell lines: human bronchial epithelial cells (Human bronchial epithelial cells, HBE), rat primary bronchial smooth muscle cells (Bronchial smooth muscle cells, BSMC), purchased from Qishi Biot...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a preparation method of a high-throughput airway inflammatory drug screening cell model based on an NF-kappaB signaling pathway, and an application of the cell model. The preparation method uses a bronchial smooth muscle cell or a bronchial epithelial cell as a source cell, NF-kappaB in the cell is activated by a stimulating factor, and the total NF-kappaB ratio and the phosphorylated NF-kappaB ratio in the cell are detected by a homogeneous time-resolved fluorescence technique to obtain the phosphorylation level of NF-kappaB; and parameters are adjusted to make a ratioof the phosphorylation level of NF-kappaB in a model group cell to the phosphorylation level of NF-kappaB in a normal group cell be equal to or more than 1.2 in order to obtain the cell model. The inflammatory cell model is constructed by screening the influences of the type and the density of the cell and the type, the concentration and the stimulation time of the stimulating factor on the phosphorylation of NF-kappaB and detecting the phosphorylation level of NF-kappaB in the cell through an HTRF technology, so a basis is provided for screening and studying of airway inflammation drugs.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a preparation method and application of a high-throughput airway inflammation drug screening cell model based on NF-κB signaling pathway. Background technique [0002] The activation of the immune system is a very complicated process. Transcription factor nuclear factor-kappa B (NF-κB) can be activated by a variety of stimuli and control different genes and biological immune responses, and has become a widely studied immune molecules. [0003] NF-κB can induce pro-inflammatory cytokine gene transcription and affect autoimmune and acquired immune responses, and is a drug therapy target for various inflammatory diseases. NF-κB is a dimeric protein whose subunits belong to the Rel proto-oncoprotein family. In most cells, including human bronchial epithelial cells, the major inducible NF-κB consists of 50 kD (p50) and 65 kD (RelA, pre-p65) subunits. When cells are stimulated b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/071C12N5/077C12Q1/02
CPCC12N5/0625C12N5/0658C12N2501/052C12N2501/25G01N33/5008
Inventor 黄飞华朱婉萍王楠楠刘霞蔡婷婷王昱霁
Owner ZHEJIANG ACAD OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products